Developer docs
API playgroundTry for free, no card

Search company profiles

Viamet Pharmaceuticals

Full company profile

uuid0003e5s

Namestring
Viamet Pharmaceuticals
Legal namestring
Metaverde, LLC
Websiteurl
viamet.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Viamet Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Morrisville, North Carolina, founded in 2005 to discover and develop small molecule therapeutics. The company's platform centers on proprietary metalloenzyme inhibitor chemistry — designing small molecules that bind metal-containing enzyme active sites — applied initially to anti-infective disease, with lead assets targeting fungal infections. Viamet has historically operated as a venture-backed platform biotech, raising cumulative equity of approximately $99.6M across 12 disclosed financings between 2005 and 2016 from a syndicate that includes Hatteras Venture Partners, Novartis Venture Fund, Lilly Ventures, Astellas Venture Management, and Intersouth Partners, alongside $1.95M of non-dilutive funding from the U.S. Department of Defense in 2015 for biodefense-relevant infectious disease work.

The company runs on a venture-funded clinical development model: multi-round venture financing is used to advance proprietary small-molecule candidates through IND-enabling studies and Phase 2/3 trials toward eventual FDA approval and commercial out-licensing or partnership with larger pharmaceutical companies. Notable strategic events include a $60M Series C in October 2014 led by Hatteras Venture Partners — the company's largest capital event — and a 2022 transaction with Acacia Research, an IP-holding vehicle that typically monetizes patent portfolios, suggesting asset divestiture, patent licensing, or a wind-down scenario rather than an active commercial launch. No revenue, commercial product, or named customers are disclosed in the input; the company is pre-revenue from a product standpoint.

The lead signals point to a narrow, specialty pharmaceutical focus on antifungal therapeutics and recurrent infections, with a small headcount (11–50 employees) consistent with a Phase 2/3 sponsor model rather than a fully integrated commercial operation. The input does not name a CEO or scientific founder beyond Chairman Robert Schotzinger, nor does it disclose a post-2016 approval, partnership, or commercial milestone. Note: a separate lead-generation website branded "Viamet" and operated by Metaverde, LLC also appears in the scraped content describing medical-travel/navigation services; this is treated as an unrelated entity and is not part of Viamet Pharmaceuticals' product or revenue set based on firmographic identification.

Short descriptiontext

Viamet Pharmaceuticals is a venture-backed, clinical-stage biopharmaceutical company founded in 2005 in Morrisville, NC, developing small molecule metalloenzyme inhibitors primarily to treat fungal and infectious diseases, with no disclosed commercial revenue or approved product.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
small molecule inhibitors, drug discovery services, metalloenzyme therapeutics, pharmaceutical development, novel therapeutic compounds
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Lead Generation Services
TypeProfessional Services
Description

The website collects user inquiries through contact forms and routes them for follow-up. The service is described as informational and lead-generation focused, with no explicit revenue model disclosed. It appears to generate value through inquiry collection rather than direct product sales.

viamet.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Viamet Pharmaceuticals discovers and develops small molecule inhibitors using a proprietary enzyme (metalloenzyme) binding approach for the treatment of various diseases. The company is a clinical-stage biopharmaceutical firm focused on identifying and advancing novel therapeutic compounds through its specialized chemistry platform, with operations spanning Morrisville, North Carolina.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Viamet is a single-offering informational and lead-generation website operated by Metaverde, LLC. The core product is the Care Navigation and Medical Travel Checklist, which serves as a lead magnet to collect user inquiries. The website provides educational blog content covering health navigation, medical travel support, care coordination questions, wellness information, and responsible provider research. No paid products, modules, or premium tiers are offered — all content and the checklist are freely accessible informational resources.

Product and service1 record
1Small molecule metalloenzyme inhibitor drug candidates
CategoryPharmaceutical R&D Pipeline
Description

Novel small molecule therapeutic compounds discovered and developed using Viamet's proprietary enzyme (metalloenzyme) binding approach, advanced for the treatment of various diseases through internal R&D and external pharmaceutical partnerships.

Partnership4 partners
1Metaverde, LLC
Strategic tierParent_CompanyTypeOthers
Description

Metaverde, LLC owns and operates the Viamet website. It is part of a broader network for education, media, and business development.

viamet.com
2Maicol
Strategic tierMinorTypeOthers
Description

Connected entity within a broader network for education, media, and business development.

viamet.com
Strategic tierMinorTypeOthers
Description

Connected entity within a broader network for education, media, and business development.

4Develop University
Strategic tierMinorTypeOthers
Description

Connected entity within a broader network for education, media, and business development.

viamet.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viamet Pharmaceuticals

Pharmaceutical Drug Discoveryviamet.com

Viamet Pharmaceuticals is a venture-backed, clinical-stage biopharmaceutical company founded in 2005 in Morrisville, NC, developing small molecule metalloenzyme inhibitors primarily to treat fungal and infectious diseases, with no disclosed commercial revenue or approved product.

What Viamet Pharmaceuticals does

Viamet Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Morrisville, North Carolina, founded in 2005 to discover and develop small molecule therapeutics. The company's platform centers on proprietary metalloenzyme inhibitor chemistry — designing small molecules that bind metal-containing enzyme active sites — applied initially to anti-infective disease, with lead assets targeting fungal infections. Viamet has historically operated as a venture-backed platform biotech, raising cumulative equity of approximately $99.6M across 12 disclosed financings between 2005 and 2016 from a syndicate that includes Hatteras Venture Partners, Novartis Venture Fund, Lilly Ventures, Astellas Venture Management, and Intersouth Partners, alongside $1.95M of non-dilutive funding from the U.S. Department of Defense in 2015 for biodefense-relevant infectious disease work.

The company runs on a venture-funded clinical development model: multi-round venture financing is used to advance proprietary small-molecule candidates through IND-enabling studies and Phase 2/3 trials toward eventual FDA approval and commercial out-licensing or partnership with larger pharmaceutical companies. Notable strategic events include a $60M Series C in October 2014 led by Hatteras Venture Partners — the company's largest capital event — and a 2022 transaction with Acacia Research, an IP-holding vehicle that typically monetizes patent portfolios, suggesting asset divestiture, patent licensing, or a wind-down scenario rather than an active commercial launch. No revenue, commercial product, or named customers are disclosed in the input; the company is pre-revenue from a product standpoint.

The lead signals point to a narrow, specialty pharmaceutical focus on antifungal therapeutics and recurrent infections, with a small headcount (11–50 employees) consistent with a Phase 2/3 sponsor model rather than a fully integrated commercial operation. The input does not name a CEO or scientific founder beyond Chairman Robert Schotzinger, nor does it disclose a post-2016 approval, partnership, or commercial milestone. Note: a separate lead-generation website branded "Viamet" and operated by Metaverde, LLC also appears in the scraped content describing medical-travel/navigation services; this is treated as an unrelated entity and is not part of Viamet Pharmaceuticals' product or revenue set based on firmographic identification.

Viamet Pharmaceuticals firmographics

Firmographics
Name
Viamet Pharmaceuticals
Legal name
Metaverde, LLC
Website
https://viamet.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Viamet Pharmaceuticals is a venture-backed, clinical-stage biopharmaceutical company founded in 2005 in Morrisville, NC, developing small molecule metalloenzyme inhibitors primarily to treat fungal and infectious diseases, with no disclosed commercial revenue or approved product.
Ownership category
akta.pro rank

Viamet Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Drug Discovery
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Small molecule inhibitors
  • Drug discovery services
  • Metalloenzyme therapeutics
  • Pharmaceutical development
  • Novel therapeutic compounds

Where Viamet Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

Viamet Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Lead Generation Services: The website collects user inquiries through contact forms and routes them for follow-up. The service is described as informational and lead-generation focused, with no explicit revenue model disclosed. It appears to generate value through inquiry collection rather than direct product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Viamet Pharmaceuticals product offering

Product offering

Core offering

Viamet Pharmaceuticals discovers and develops small molecule inhibitors using a proprietary enzyme (metalloenzyme) binding approach for the treatment of various diseases. The company is a clinical-stage biopharmaceutical firm focused on identifying and advancing novel therapeutic compounds through its specialized chemistry platform, with operations spanning Morrisville, North Carolina.

Product overview

Viamet is a single-offering informational and lead-generation website operated by Metaverde, LLC. The core product is the Care Navigation and Medical Travel Checklist, which serves as a lead magnet to collect user inquiries. The website provides educational blog content covering health navigation, medical travel support, care coordination questions, wellness information, and responsible provider research. No paid products, modules, or premium tiers are offered — all content and the checklist are freely accessible informational resources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Small molecule metalloenzyme inhibitor drug candidates Novel small molecule therapeutic compounds discovered and developed using Viamet's proprietary enzyme (metalloenzyme) binding approach, advanced for the treatment of various diseases through internal R&D and external pharmaceutical partnerships.

Companies that use Viamet Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Viamet Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Viamet Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered parent_company and minor.

  • Metaverde, LLCparent_companyOthersMetaverde, LLC owns and operates the Viamet website. It is part of a broader network for education, media, and business development.
  • MaicolminorOthersConnected entity within a broader network for education, media, and business development.
  • Maicol El FamosominorOthersConnected entity within a broader network for education, media, and business development.
  • Develop UniversityminorOthersConnected entity within a broader network for education, media, and business development.

Recent moves6 records

Expansion highlights4 records

Viamet Pharmaceuticals competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Viamet Pharmaceuticals social profiles

Digital presence

Viamet Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viamet Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Viamet Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viamet Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viamet Pharmaceuticals

What does Viamet Pharmaceuticals do?

Viamet Pharmaceuticals discovers and develops small molecule inhibitors using a proprietary enzyme (metalloenzyme) binding approach for the treatment of various diseases. The company is a clinical-stage biopharmaceutical firm focused on identifying and advancing novel therapeutic compounds through its specialized chemistry platform, with operations spanning Morrisville, North Carolina.

Is Viamet Pharmaceuticals a public or private company?

Viamet Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Viamet Pharmaceuticals founded?

Viamet Pharmaceuticals was founded in 2005. It employs 1 to 10 people.

Where is Viamet Pharmaceuticals based?

Viamet Pharmaceuticals is headquartered in Durham, United States, in the North America region.

How does Viamet Pharmaceuticals make money?

One revenue line is on record: lead Generation Services.

Does Viamet Pharmaceuticals have an API?

No public API is recorded for Viamet Pharmaceuticals.

What industry is Viamet Pharmaceuticals in?

Viamet Pharmaceuticals's product category is Pharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAHAA, Small-Molecule API Process Development & Route Scouting. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAcacia Research Reports Second Quarter 2022 Financial ResultsAcacia Research Corporation reported a GAAP net loss of $61.5 million for the second quarter of 2022, driven by $57.6 million in unrealized losses on equity securities and non-cash derivative liabilities, despite generating $16.7 million in revenue and $11.5 million in realized gains. The company completed a $40 million share repurchase program and repaid $50 million of debt to Starboard Value LP during the period. Additionally, Acacia is anticipating a $26.7 million milestone payment from Viamet Pharmaceuticals following FDA approval of its drug VIVJOA.StltodayNew role in publishing for former Washington University provostHolden Thorp, who announced a year-long sabbatical from Washington University in June, has been named editor-in-chief of Science journals. He will take a leave from Washington University in St. Louis to assume the role.News-MedicalMycovia initiates two Phase 3 clinical trials to evaluate VT-1161 in patients with RVVCMycovia Pharmaceuticals initiated two Phase 3 trials (VIOLET) to evaluate VT-1161 for recurrent vulvovaginal candidiasis. The trials will enroll about 300 patients per study across 60 global sites, with completion expected in the second half of 2020. The company anticipates regulatory submissions in the U.S., EU, and Japan.PR NewswireGlobal Antifungal Drugs Market, 2021: Increased Availability of Generics and Alternative Therapies - Research and MarketsResearch and Markets added a report on the global antifungal drugs market for 2017-2021, projecting a CAGR of 3.20%. The report cites rising OTC popularity and drug resistance as key drivers and challenges, with major vendors including Pfizer, Merck, and Novartis.PR NewswireMeningitis Pipeline Landscape and Therapeutics Market 2016 Review ResearchReportsnReports.com released a H1 2016 meningitis pipeline review covering drug profiles, key players, and late-stage projects. The report includes 25 market data tables and 14 figures across 63 pages, with drug profiles such as amphotericin B and vaccines. It highlights unmet needs for serogroup B meningococcal meningitis.